{"disease":{"id":"metastatic-cancer","name":"metastatic cancer"},"drugs":{"marketed":[{"drug_id":"palbociclib-in-combination-with-ai","indication_name":"Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HER2-negative) advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women with estrogen receptor-positive (ER+), HER2-negative breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib in combination with AI","generic_name":"palbociclib-in-combination-with-ai","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CDK4/6","drug_class":"CDK inhibitor","quality_score":50,"revenue":"4122","mechanism":""},{"drug_id":"palbociclib-in-combination-with-ai","indication_name":"Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-negative) advanced or metastatic breast cancer in combination with fulvestrant in women with disease progression following endocrine therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib in combination with AI","generic_name":"palbociclib-in-combination-with-ai","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CDK4/6","drug_class":"CDK inhibitor","quality_score":50,"revenue":"4122","mechanism":""},{"drug_id":"atezolizumab","indication_name":"Metastatic non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tecentriq","generic_name":"atezolizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"3700","mechanism":"Tecentriq works by blocking a protein called PD-L1, which helps cancer cells hide from the immune system."},{"drug_id":"atezolizumab","indication_name":"Germline BRCA-mutated, HER2-negative metastatic breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tecentriq","generic_name":"atezolizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"3700","mechanism":"Tecentriq works by blocking a protein called PD-L1, which helps cancer cells hide from the immune system."},{"drug_id":"lee011","indication_name":"Initial endocrine-based therapy for advanced or metastatic breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kisqali","generic_name":"LEE011","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Cyclin-dependent kinase 4","drug_class":"Kinase Inhibitor","quality_score":66,"revenue":"3600","mechanism":"Kisqali works by blocking a protein called cyclin-dependent kinase 4, which helps cancer cells grow and divide."},{"drug_id":"ipilimumab","indication_name":"Metastatic nonsmall cell lung cancer with no sensitising EGFR mutation or ALK translocation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Yervoy","generic_name":"ipilimumab","company_name":"Bristol-Myers Squibb","drug_phase":"discontinued","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"CTLA-4-directed Blocking Antibody","quality_score":0,"revenue":"2900","mechanism":"Yervoy blocks a protein called CTLA-4, which normally helps to turn off the immune system, allowing it to attack cancer cells."},{"drug_id":"cabometyx","indication_name":"Progressive, Metastatic Medullary Thyroid Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cometriq","generic_name":"Cabometyx","company_name":"Exelixis","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor receptor 2","drug_class":"Kinase Inhibitor","quality_score":70,"revenue":"2200","mechanism":"Cometriq blocks the VEGFR2 pathway to prevent tumor growth and angiogenesis."},{"drug_id":"talazoparib-with-enzalutamide","indication_name":"Metastatic castration-resistant prostate cancer (mCRPC) with BRCA1, BRCA2, or ATM gene mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Talazoparib with enzalutamide","generic_name":"talazoparib-with-enzalutamide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PARP enzymes and androgen receptor","drug_class":"PARP inhibitor and androgen receptor inhibitor","quality_score":10,"revenue":"2194","mechanism":""},{"drug_id":"darolutamide","indication_name":"Metastatic castration-sensitive prostate cancer (mCSPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nubeqa","generic_name":"darolutamide","company_name":"Bayer","drug_phase":"marketed","molecular_target":"androgen receptor (AR)","drug_class":"","quality_score":76,"revenue":"1600","mechanism":"Darolutamide inhibits androgen receptor activity, reducing prostate cancer cell growth and tumor size."},{"drug_id":"darolutamide","indication_name":"Non-metastatic castration-resistant prostate cancer (nmCRPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nubeqa","generic_name":"darolutamide","company_name":"Bayer","drug_phase":"marketed","molecular_target":"androgen receptor (AR)","drug_class":"","quality_score":76,"revenue":"1600","mechanism":"Darolutamide inhibits androgen receptor activity, reducing prostate cancer cell growth and tumor size."},{"drug_id":"darolutamide","indication_name":"Metastatic prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nubeqa","generic_name":"darolutamide","company_name":"Bayer","drug_phase":"marketed","molecular_target":"androgen receptor (AR)","drug_class":"","quality_score":76,"revenue":"1600","mechanism":"Darolutamide inhibits androgen receptor activity, reducing prostate cancer cell growth and tumor size."},{"drug_id":"darolutamide","indication_name":"Metastatic castration-sensitive prostate cancer (mCSPC) with docetaxel","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nubeqa","generic_name":"darolutamide","company_name":"Bayer","drug_phase":"marketed","molecular_target":"androgen receptor (AR)","drug_class":"","quality_score":76,"revenue":"1600","mechanism":"Darolutamide inhibits androgen receptor activity, reducing prostate cancer cell growth and tumor size."},{"drug_id":"abiraterone","indication_name":"Chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abiraterone Acetate","generic_name":"abiraterone","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CYP17","drug_class":"Androgen biosynthesis inhibitor","quality_score":67,"revenue":"1500","mechanism":"Abiraterone is an androgen biosynthesis inhibitor that targets CYP17 to reduce androgen production in prostate cancer cells."},{"drug_id":"abiraterone","indication_name":"Metastatic castration-resistant prostate cancer (mCRPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abiraterone Acetate","generic_name":"abiraterone","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CYP17","drug_class":"Androgen biosynthesis inhibitor","quality_score":67,"revenue":"1500","mechanism":"Abiraterone is an androgen biosynthesis inhibitor that targets CYP17 to reduce androgen production in prostate cancer cells."},{"drug_id":"abiraterone","indication_name":"Metastatic high-risk castration-sensitive prostate cancer (mHSPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abiraterone Acetate","generic_name":"abiraterone","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CYP17","drug_class":"Androgen biosynthesis inhibitor","quality_score":67,"revenue":"1500","mechanism":"Abiraterone is an androgen biosynthesis inhibitor that targets CYP17 to reduce androgen production in prostate cancer cells."},{"drug_id":"abiraterone-acetate","indication_name":"Metastatic castration-resistant prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zytiga","generic_name":"abiraterone-acetate","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Steroid 17-alpha-hydroxylase/17,20 lyase","drug_class":"Cytochrome P450 17A1 Inhibitor","quality_score":64,"revenue":"1500","mechanism":"Zytiga blocks the production of male hormones that fuel prostate cancer growth."},{"drug_id":"trastuzumab-emtansine","indication_name":"Treatment of HER2-positive unresectable or metastatic breast cancer in patients who have received prior anti-HER2-based therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kadcyla","generic_name":"trastuzumab-emtansine","company_name":"Roche","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"Antibody-drug conjugate","quality_score":10,"revenue":"900","mechanism":"Trastuzumab emtansine is a HER2-targeted antibody-drug conjugate that works by binding to the HER2 receptor and releasing a cytotoxic agent."},{"drug_id":"amivantamab","indication_name":"Advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rybrevant","generic_name":"AMIVANTAMAB","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"EGFR, MET","drug_class":"","quality_score":59,"revenue":"800","mechanism":"Amivantamab-vmjw targets EGFR and MET, disrupting their signaling and enhancing immune cell-mediated destruction of tumor cells."},{"drug_id":"lorlatinib-with-chemotherapy-2","indication_name":"Anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) with brain metastases","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lorlatinib with chemotherapy 2","generic_name":"lorlatinib-with-chemotherapy-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"ALK","drug_class":"ALK inhibitor","quality_score":40,"revenue":"798","mechanism":""},{"drug_id":"selpercatinib","indication_name":"Metastatic non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Retevmo","generic_name":"SELPERCATINIB","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Proto-oncogene tyrosine-protein kinase receptor Ret","drug_class":"Kinase Inhibitor [EPC]","quality_score":69,"revenue":"700","mechanism":"Retevmo works by blocking the activity of the RET protein, which is involved in the growth and spread of cancer cells."},{"drug_id":"tremelimumab","indication_name":"Metastatic non-small cell lung cancer with no anaplastic lymphoma kinase genomic tumor aberrations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imjudo","generic_name":"TREMELIMUMAB","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"CTLA-4","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":62,"revenue":"400","mechanism":"Tremelimumab-actl binds to CTLA-4, blocking its interaction with CD80 and CD86, thereby enhancing T-cell activation and reducing tumor growth."},{"drug_id":"tetraxetan","indication_name":"metastatic castration-resistant prostate cancer (mCRPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pluvicto","generic_name":"TETRAXETAN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"","drug_class":"Radioligand Therapeutic Agent [EPC]","quality_score":10,"revenue":"386","mechanism":"Pluvicto works by binding to the PSMA protein on prostate cancer cells, delivering a radioactive payload to destroy the cancer cells."},{"drug_id":"tetraxetan","indication_name":"metastatic castration-resistant prostate cancer (mCRPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pluvicto","generic_name":"TETRAXETAN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"","drug_class":"Radioligand Therapeutic Agent [EPC]","quality_score":10,"revenue":"386","mechanism":"Pluvicto works by binding to the PSMA protein on prostate cancer cells, delivering a radioactive payload to destroy the cancer cells."},{"drug_id":"lutetium-177lu-vipivotide-tetraxetan","indication_name":"PSMA-positive metastatic castration-resistant prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pluvicto","generic_name":"Lutetium (177Lu) vipivotide tetraxetan","company_name":"Aaa Usa Novartis","drug_phase":"marketed","molecular_target":"Prostate-specific antigen","drug_class":"Radioligand Therapeutic Agent [EPC]","quality_score":45,"revenue":"386","mechanism":"Pluvicto works by binding to prostate-specific antigen (PSMA) on cancer cells, delivering a radioactive payload that kills the cells."},{"drug_id":"sotorasib","indication_name":"KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lumakras","generic_name":"SOTORASIB","company_name":"Amgen","drug_phase":"marketed","molecular_target":"GTPase KRas","drug_class":"","quality_score":65,"revenue":"300","mechanism":"Lumakras works by covalently binding to the KRAS G12C mutation, thereby blocking the protein's ability to promote cancer cell growth."},{"drug_id":"adagrasib","indication_name":"KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Krazati","generic_name":"ADAGRASIB","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"GTPase KRas","drug_class":"","quality_score":66,"revenue":"205","mechanism":"Krazati works by binding to and inhibiting the GTPase activity of the KRAS G12C protein, preventing it from sending signals that promote cancer cell growth."},{"drug_id":"repotrectinib","indication_name":"Locally advanced or metastatic ROS1-positive non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Augtyro","generic_name":"REPOTRECTINIB","company_name":"Bristol","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":60,"revenue":"200","mechanism":"Augtyro blocks the activity of ROS1 and NTRK kinases, which are abnormal proteins that help cancer cells grow and spread."},{"drug_id":"capmatinib","indication_name":"Metastatic non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tabrecta","generic_name":"CAPMATINIB","company_name":"Novartis Pharm","drug_phase":"marketed","molecular_target":"Hepatocyte growth factor receptor","drug_class":"Kinase Inhibitor","quality_score":66,"revenue":"200","mechanism":"Tabrecta works by blocking the hepatocyte growth factor receptor, a protein that helps cancer cells grow and spread."},{"drug_id":"talzenna","indication_name":"BRCA-mutated (g BRCA m) HER2-negative Locally Advanced or Metastatic Breast Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Talzenna","generic_name":"Talazoparib Tosylate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"PARP1 and PARP2 enzymes","drug_class":"PARP inhibitor","quality_score":75,"revenue":"182","mechanism":"PARP1/PARP2 inhibitor causing DNA damage, decreased proliferation, and apoptosis in BRCA-mutated cancers."},{"drug_id":"talzenna","indication_name":"HRR Gene-mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Talzenna","generic_name":"Talazoparib Tosylate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"PARP1 and PARP2 enzymes","drug_class":"PARP inhibitor","quality_score":75,"revenue":"182","mechanism":"PARP1/PARP2 inhibitor causing DNA damage, decreased proliferation, and apoptosis in BRCA-mutated cancers."},{"drug_id":"talazoparib","indication_name":"Germline BRCA-mutated, HER2-negative metastatic breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Talzenna","generic_name":"talazoparib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Poly [ADP-ribose] polymerase 4","drug_class":"Poly(ADP-Ribose) Polymerase Inhibitor","quality_score":72,"revenue":"182","mechanism":"Talzenna blocks PARP enzymes, which are involved in DNA repair, to prevent cancer cell growth."},{"drug_id":"talazoparib-tosylate","indication_name":"Germline BRCA-mutated, HER2-negative metastatic breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Talzenna","generic_name":"talazoparib-tosylate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PARP1, PARP2","drug_class":"Poly(ADP-Ribose) Polymerase Inhibitor","quality_score":75,"revenue":"182","mechanism":"Talazoparib inhibits PARP enzymes, causing DNA damage and cell death in cancer cells with DNA repair defects."},{"drug_id":"tisotumab-vedotin","indication_name":"Recurrent or metastatic cervical cancer with disease progression on or after chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tivdak","generic_name":"tisotumab-vedotin","company_name":"SEAGEN","drug_phase":"marketed","molecular_target":"Tissue factor","drug_class":"Antibody-drug conjugate","quality_score":10,"revenue":"147","mechanism":"Tisotumab vedotin is a tissue factor (TF)-directed antibody drug conjugate that targets and disrupts microtubule networks in cancer cells."},{"drug_id":"tisotumab","indication_name":"recurrent or metastatic cervical cancer with disease progression on or after chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tivdak","generic_name":"TISOTUMAB","company_name":"Seagen","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":64,"revenue":"147","mechanism":"Tivdak works by binding to a specific target on cancer cells, triggering an immune response to destroy the cancer."},{"drug_id":"tivdak","indication_name":"Treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tisotumab Vedotin","generic_name":"tivdak","company_name":"SEAGEN","drug_phase":"marketed","molecular_target":"Tissue factor","drug_class":"Antibody-Drug Conjugate (ADC)","quality_score":10,"revenue":"147","mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic triple-negative breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic colorectal cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic biliary tract cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic anal cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic penile cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic vulvar cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic cervical cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic endometrial cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic ovarian cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic fallopian tube cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic primary peritoneal cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic pancreatic cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic thyroid cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"ensartinib","indication_name":"ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ensacove","generic_name":"ENSARTINIB","company_name":"Xcovery","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":49,"revenue":null,"mechanism":"Ensartinib works by inhibiting a specific protein that drives the growth of cancer cells."},{"drug_id":"deruxtecan","indication_name":"Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Datroway","generic_name":"DERUXTECAN","company_name":"Daiichi Sankyo","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":44,"revenue":null,"mechanism":"Deruxtecan works by binding to and inhibiting the growth of cancer cells."},{"drug_id":"deruxtecan","indication_name":"Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Datroway","generic_name":"DERUXTECAN","company_name":"Daiichi Sankyo","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":44,"revenue":null,"mechanism":"Deruxtecan works by binding to and inhibiting the growth of cancer cells."},{"drug_id":"mobocertinib","indication_name":"Advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Exkivity","generic_name":"MOBOCERTINIB","company_name":"Takeda","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-4","drug_class":"Kinase Inhibitor","quality_score":28,"revenue":null,"mechanism":""},{"drug_id":"elacestrant","indication_name":"ESR1-mutated advanced or metastatic breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Orserdu","generic_name":"ELACESTRANT","company_name":"Stemline Therap","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen Receptor Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":"Orserdu works by blocking the estrogen receptor, a protein that helps cancer cells grow."},{"drug_id":"elacestrant","indication_name":"Estrogen receptor positive advanced or metastatic breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Orserdu","generic_name":"ELACESTRANT","company_name":"Stemline Therap","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen Receptor Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":"Orserdu works by blocking the estrogen receptor, a protein that helps cancer cells grow."},{"drug_id":"elacestrant","indication_name":"HER2-negative advanced or metastatic breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Orserdu","generic_name":"ELACESTRANT","company_name":"Stemline Therap","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen Receptor Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":"Orserdu works by blocking the estrogen receptor, a protein that helps cancer cells grow."},{"drug_id":"telisotuzumab","indication_name":"locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Emrelis","generic_name":"TELISOTUZUMAB","company_name":"Abbvie Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":53,"revenue":null,"mechanism":"Emrelis binds to the c-Met protein on cancer cells, blocking its growth-promoting signals."},{"drug_id":"mitomycin","indication_name":"Metastatic Gastric Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mitozytrex","generic_name":"MITOMYCIN","company_name":"Kyowa Kirin Co., Ltd.","drug_phase":"marketed","molecular_target":"Indoleamine 2,3-dioxygenase 1","drug_class":"Alkylating Drug [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"chembl-chembl254328","indication_name":"Metastatic castration-resistant prostate cancer (CRPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abiraterone Acetate","generic_name":"ABIRATERONE","company_name":"Janssen Biotech","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":42,"revenue":null,"mechanism":"Abiraterone Acetate blocks the production of androgens, which are hormones that prostate cancer cells need to grow."},{"drug_id":"chembl-chembl254328","indication_name":"Metastatic high-risk castration-sensitive prostate cancer (CSPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abiraterone Acetate","generic_name":"ABIRATERONE","company_name":"Janssen Biotech","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":42,"revenue":null,"mechanism":"Abiraterone Acetate blocks the production of androgens, which are hormones that prostate cancer cells need to grow."},{"drug_id":"palbociclib","indication_name":"Treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib","generic_name":"palbociclib","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cyclin-dependent kinases 4 and 6 (CDK4/6)","drug_class":"CDK4/6 inhibitor","quality_score":70,"revenue":null,"mechanism":"Palbociclib inhibits CDK4/6 to block G1/S cell cycle progression in ER-positive breast cancer."},{"drug_id":"palbociclib","indication_name":"Treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with fulvestrant in patients with disease progression following endocrine therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib","generic_name":"palbociclib","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cyclin-dependent kinases 4 and 6 (CDK4/6)","drug_class":"CDK4/6 inhibitor","quality_score":70,"revenue":null,"mechanism":"Palbociclib inhibits CDK4/6 to block G1/S cell cycle progression in ER-positive breast cancer."},{"drug_id":"palbociclib","indication_name":"Treatment of adult patients with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy, in combination with inavolisib and fulvestrant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib","generic_name":"palbociclib","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cyclin-dependent kinases 4 and 6 (CDK4/6)","drug_class":"CDK4/6 inhibitor","quality_score":70,"revenue":null,"mechanism":"Palbociclib inhibits CDK4/6 to block G1/S cell cycle progression in ER-positive breast cancer."},{"drug_id":"doxorubicin-hydrochloride","indication_name":"Metastatic breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Doxorubicin Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, nucleotide bases","drug_class":"Anthracycline topoisomerase inhibitor","quality_score":70,"revenue":null,"mechanism":"Doxorubicin intercalates nucleotide bases and interacts with topoisomerase II to form DNA-cleavable complexes, inhibiting DNA/RNA replication."},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed oxaliplatin-based chemotherapy.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic breast cancer in postmenopausal women with one or more estrogen receptors and/or progesterone receptors and a HER2-negative tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic breast cancer in postmenopausal women with one or more estrogen receptors and/or progesterone receptors and a HER2-positive tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic non-small cell lung cancer with an activating EGFR mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic non-small cell lung cancer with a tumor harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-negative tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Metastatic colorectal cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"First-line treatment of metastatic colorectal cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Second-line treatment of metastatic colorectal cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of unresectable or metastatic colorectal cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"capecitabine","indication_name":"Treatment of unresectable or metastatic colorectal cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeloda","generic_name":"capecitabine","company_name":"Cheplapharm","drug_phase":"marketed","molecular_target":"Thymidylate synthase","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":67,"revenue":null,"mechanism":"Xeloda works by inhibiting the enzyme thymidylate synthase, which is necessary for DNA synthesis in cancer cells."},{"drug_id":"hydroxydaunorubicin","indication_name":"Metastatic Gastric Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunorubicin","company_name":"University of Colorado, Denver","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zenocutuzumab","indication_name":"advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bizengri","generic_name":"ZENOCUTUZUMAB","company_name":"Merus N.V.","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Bizengri works by binding to a specific protein on cancer cells to block their growth and spread."},{"drug_id":"yervoy","indication_name":"Metastatic nonsmall cell lung cancer with no sensitising EGFR mutation or ALK translocation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Yervoy","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"amivantamab-vmjw","indication_name":"Advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"RYBREVANT","generic_name":"AMIVANTAMAB-VMJW","company_name":"JANSSEN BIOTECH","drug_phase":"marketed","molecular_target":"Epidermal growth factor receptor, Hepatocyte growth factor receptor","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"tremelimumab-actl","indication_name":"Metastatic non-small cell lung cancer with no anaplastic lymphoma kinase genomic tumor aberrations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"IMJUDO","generic_name":"TREMELIMUMAB-ACTL","company_name":"ASTRAZENECA AB","drug_phase":"marketed","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"zytiga","indication_name":"Metastatic castration-resistant prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zytiga","company_name":"Bukwang Pharmaceutical","drug_phase":"marketed","molecular_target":"Cytochrome P450 11B2, mitochondrial, Androgen receptor, Cytochrome P450 11B1, mitochondrial","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"fulvestrant","indication_name":"Metastatic Breast Cancer Progression Post-Antiestrogen Therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Faslodex","generic_name":"fulvestrant","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Progesterone receptor","drug_class":"Estrogen Receptor Antagonist [EPC]","quality_score":58,"revenue":null,"mechanism":"Faslodex works by binding to and degrading the estrogen receptor, preventing it from promoting the growth of cancer cells."},{"drug_id":"alpelisib","indication_name":"Germline BRCA-mutated, HER2-negative metastatic breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Piqray","generic_name":"alpelisib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"PI3Kα","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Alpelisib inhibits PI3Kα, blocking Akt-signaling and preventing tumor growth and organ abnormalities in PROS disorders."},{"drug_id":"zongertinib","indication_name":"unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hernexeos","generic_name":"ZONGERTINIB","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Hernexeos works by blocking the HER2 tyrosine kinase domain, which is a protein that helps cancer cells grow and divide."},{"drug_id":"zongertinib","indication_name":"unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hernexeos","generic_name":"ZONGERTINIB","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Hernexeos works by blocking the HER2 tyrosine kinase domain, which is a protein that helps cancer cells grow and divide."},{"drug_id":"imlunestrant","indication_name":"ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inluriyo","generic_name":"IMLUNESTRANT","company_name":"Eli Lilly And Co","drug_phase":"marketed","molecular_target":"","drug_class":"Estrogen Receptor Antagonist [EPC]","quality_score":61,"revenue":null,"mechanism":"Inluriyo works by blocking estrogen receptors on cancer cells, preventing them from growing and spreading."},{"drug_id":"imlunestrant","indication_name":"ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inluriyo","generic_name":"IMLUNESTRANT","company_name":"Eli Lilly And Co","drug_phase":"marketed","molecular_target":"","drug_class":"Estrogen Receptor Antagonist [EPC]","quality_score":61,"revenue":null,"mechanism":"Inluriyo works by blocking estrogen receptors on cancer cells, preventing them from growing and spreading."},{"drug_id":"taletrectinib","indication_name":"locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ibtrozi","generic_name":"TALETRECTINIB","company_name":"Nuvation","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Ibtrozi works by blocking the ROS1 protein, which is a genetic mutation found in some lung cancer cells."},{"drug_id":"folfox-7","indication_name":"Metastatic colorectal cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfox-7","generic_name":"folfox-7","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication machinery","drug_class":"chemotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"liposomal-doxorubicin","indication_name":"Metastatic Gastric Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Liposomal Doxorubicin","generic_name":"liposomal-doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase","drug_class":"doxorubicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"fulvestrant-injectable-product","indication_name":"Advanced breast cancer in hormone receptor-positive metastatic breast cancer in patients with disease progression on or after prior chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fulvestrant Injectable Product","generic_name":"fulvestrant-injectable-product","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"estrogen receptor","drug_class":"estrogen receptor degrader","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"fulvestrant-injectable-product","indication_name":"Advanced breast cancer in hormone receptor-positive metastatic breast cancer in patients with disease progression on or after prior endocrine therapy and prior chemotherapy in the metastatic setting","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fulvestrant Injectable Product","generic_name":"fulvestrant-injectable-product","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"estrogen receptor","drug_class":"estrogen receptor degrader","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"trametinib","indication_name":"Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mekinist","generic_name":"trametinib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Dual specificity mitogen-activated protein kinase kinase 2","drug_class":"Kinase Inhibitor","quality_score":71,"revenue":null,"mechanism":"Mekinist works by blocking a specific enzyme called BRAF V600E, which is involved in the growth and spread of cancer cells."},{"drug_id":"trametinib","indication_name":"Metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mekinist","generic_name":"trametinib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Dual specificity mitogen-activated protein kinase kinase 2","drug_class":"Kinase Inhibitor","quality_score":71,"revenue":null,"mechanism":"Mekinist works by blocking a specific enzyme called BRAF V600E, which is involved in the growth and spread of cancer cells."},{"drug_id":"pralsetinib","indication_name":"Metastatic non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gavreto","generic_name":"PRALSETINIB","company_name":"Rigel Pharms","drug_phase":"marketed","molecular_target":"RET","drug_class":"Kinase Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Pralsetinib inhibits RET kinase and its oncogenic fusions/mutations, blocking downstream signaling and reducing tumor growth."},{"drug_id":"doxorubicin","indication_name":"Metastatic Gastric Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Doxorubicin Hydrochloride","generic_name":"doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aurora kinase A","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA strands and inhibiting topoisomerase II, an enzyme essential for DNA replication and cell division."},{"drug_id":"chembl-chembl4650215","indication_name":"endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Itovebi","generic_name":"INAVOLISIB","company_name":"Genentech Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":53,"revenue":null,"mechanism":"Itovebi works by blocking a specific enzyme called PIK3CA, which is involved in the growth and spread of cancer cells."},{"drug_id":"carbamide","indication_name":"Metastatic non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"(CARBAMIDE®)","company_name":"German University in Cairo","drug_phase":"marketed","molecular_target":"Cyclin-dependent kinase-like 5, Hepatocyte growth factor receptor","drug_class":"","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"hydroxydaunomycin","indication_name":"Metastatic Gastric Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunomycin","company_name":"Weill Medical College of Cornell University","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adriamycin","indication_name":"Metastatic Gastric Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adriamycin","company_name":"Johann Wolfgang Goethe University Hospital","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"pluvicto","indication_name":"PSMA-positive metastatic castration-resistant prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pluvicto","company_name":"VA Office of Research and Development","drug_phase":"marketed","molecular_target":"Prostate-specific antigen","drug_class":"","quality_score":11,"revenue":null,"mechanism":null},{"drug_id":"adriacin","indication_name":"Metastatic Gastric Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"adriacin","company_name":"Chipscreen Biosciences, Ltd.","drug_phase":"phase_1","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"capecitabine","indication_name":"Treatment of advanced or metastatic breast cancer (with docetaxel)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeloda","generic_name":"capecitabine","company_name":"Cheplapharm","drug_phase":"marketed","molecular_target":"Thymidylate synthase","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":67,"revenue":null,"mechanism":"Xeloda works by inhibiting the enzyme thymidylate synthase, which is necessary for DNA synthesis in cancer cells."},{"drug_id":"capecitabine","indication_name":"Treatment of advanced or metastatic breast cancer (single agent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeloda","generic_name":"capecitabine","company_name":"Cheplapharm","drug_phase":"marketed","molecular_target":"Thymidylate synthase","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":67,"revenue":null,"mechanism":"Xeloda works by inhibiting the enzyme thymidylate synthase, which is necessary for DNA synthesis in cancer cells."},{"drug_id":"capecitabine","indication_name":"Treatment of unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeloda","generic_name":"capecitabine","company_name":"Cheplapharm","drug_phase":"marketed","molecular_target":"Thymidylate synthase","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":67,"revenue":null,"mechanism":"Xeloda works by inhibiting the enzyme thymidylate synthase, which is necessary for DNA synthesis in cancer cells."},{"drug_id":"irinotecan","indication_name":"Metastatic colorectal cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Camptosar","generic_name":"irinotecan","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I","drug_class":"Topoisomerase Inhibitor","quality_score":76,"revenue":null,"mechanism":"Irinotecan and its metabolite SN-38 bind to the topoisomerase I-DNA complex, preventing DNA repair and causing double-strand breaks."},{"drug_id":"bevacizumab-maly","indication_name":"Metastatic Colorectal Cancer - First/Second Line","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ALYMSYS","generic_name":"BEVACIZUMAB-MALY","company_name":"AMNEAL PHARMS LLC","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"bevacizumab-maly","indication_name":"Metastatic Colorectal Cancer - Second Line Post Bevacizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ALYMSYS","generic_name":"BEVACIZUMAB-MALY","company_name":"AMNEAL PHARMS LLC","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"bevacizumab-maly","indication_name":"Persistent, Recurrent, or Metastatic Cervical Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ALYMSYS","generic_name":"BEVACIZUMAB-MALY","company_name":"AMNEAL PHARMS LLC","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"ixabepilone","indication_name":"Metastatic or locally advanced breast cancer with capecitabine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ixempra Kit","generic_name":"IXABEPILONE","company_name":"R-Pharm Us Llc","drug_phase":"marketed","molecular_target":"Apoptosis regulator Bcl-2","drug_class":"Microtubule Inhibitor","quality_score":64,"revenue":null,"mechanism":"Ixempra Kit works by disrupting cell division, preventing cancer cells from growing and multiplying."},{"drug_id":"ixabepilone","indication_name":"Metastatic or locally advanced breast cancer as a single agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ixempra Kit","generic_name":"IXABEPILONE","company_name":"R-Pharm Us Llc","drug_phase":"marketed","molecular_target":"Apoptosis regulator Bcl-2","drug_class":"Microtubule Inhibitor","quality_score":64,"revenue":null,"mechanism":"Ixempra Kit works by disrupting cell division, preventing cancer cells from growing and multiplying."},{"drug_id":"cabozantinib","indication_name":"Progressive, Metastatic Medullary Thyroid Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cometriq","generic_name":"CABOZANTINIB","company_name":"Exelixis Inc","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor receptor 2","drug_class":"Kinase Inhibitor","quality_score":53,"revenue":null,"mechanism":"Cometriq works by blocking the activity of vascular endothelial growth factor receptor 2, a protein involved in tumor growth and angiogenesis."},{"drug_id":"trastuzumab-anns","indication_name":"Metastatic Gastric Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"KANJINTI","generic_name":"TRASTUZUMAB-ANNS","company_name":"AMGEN INC","drug_phase":"marketed","molecular_target":"","drug_class":"HER2/neu Receptor Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"trastuzumab-anns","indication_name":"Metastatic Breast Cancer - First Line","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"KANJINTI","generic_name":"TRASTUZUMAB-ANNS","company_name":"AMGEN INC","drug_phase":"marketed","molecular_target":"","drug_class":"HER2/neu Receptor Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"trastuzumab-anns","indication_name":"Metastatic Breast Cancer - Subsequent Therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"KANJINTI","generic_name":"TRASTUZUMAB-ANNS","company_name":"AMGEN INC","drug_phase":"marketed","molecular_target":"","drug_class":"HER2/neu Receptor Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"sipuleucel-t","indication_name":"Metastatic castrate-resistant prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SIPULEUCEL-T","company_name":"","drug_phase":"marketed","molecular_target":"PAP","drug_class":"Autologous Cellular Immunotherapy [EPC]","quality_score":10,"revenue":null,"mechanism":"PROVENGE induces an immune response against PAP, an antigen found in most prostate cancers."},{"drug_id":"sipuleucel-t","indication_name":"Metastatic castrate-resistant prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SIPULEUCEL-T","company_name":"","drug_phase":"marketed","molecular_target":"PAP","drug_class":"Autologous Cellular Immunotherapy [EPC]","quality_score":10,"revenue":null,"mechanism":"PROVENGE induces an immune response against PAP, an antigen found in most prostate cancers."},{"drug_id":"chembl-chembl3183409","indication_name":"Metastatic castration-sensitive prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"APALUTAMIDE","company_name":"","drug_phase":"marketed","molecular_target":"Androgen Receptor (AR)","drug_class":"","quality_score":48,"revenue":null,"mechanism":"Apalutamide binds to the androgen receptor, blocking its function and reducing tumor growth."},{"drug_id":"chembl-chembl3183409","indication_name":"Non-metastatic castration-resistant prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"APALUTAMIDE","company_name":"","drug_phase":"marketed","molecular_target":"Androgen Receptor (AR)","drug_class":"","quality_score":48,"revenue":null,"mechanism":"Apalutamide binds to the androgen receptor, blocking its function and reducing tumor growth."},{"drug_id":"chembl-chembl1789844","indication_name":"Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IPILIMUMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1789844","indication_name":"Metastatic Non-Small Cell Lung Cancer (PD-L1 ≥1%)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IPILIMUMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1789844","indication_name":"Metastatic or Recurrent Non-Small Cell Lung Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IPILIMUMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"dactinomycin","indication_name":"Metastatic Nonseminomatous Testicular Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cosmegen","generic_name":"DACTINOMYCIN","company_name":"Recordati","drug_phase":"marketed","molecular_target":"DNA","drug_class":"Actinomycin [EPC]","quality_score":65,"revenue":null,"mechanism":"Dactinomycin binds DNA and inhibits RNA synthesis, demonstrating cytotoxic activity in cancer models."},{"drug_id":"trastuzumab-and-hyaluronidase-oysk","indication_name":"Treatment of HER2-Overexpressing Metastatic Breast Cancer After Chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Trastuzumab and Hyaluronidase-oysk","company_name":"Adrienne G. Waks","drug_phase":"marketed","molecular_target":"HER2","drug_class":"Endoglycosidase [EPC]","quality_score":10,"revenue":null,"mechanism":"Trastuzumab inhibits HER2-overexpressing tumor cell proliferation and mediates ADCC, while hyaluronidase increases subcutaneous permeability for better drug absorption."},{"drug_id":"chembl-chembl2103875","indication_name":"BRAF V600E Mutation-Positive Locally Advanced or Metastatic Anaplastic Thyroid Cancer (Combination with Dabrafenib)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TRAMETINIB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":5,"revenue":null,"mechanism":null},{"drug_id":"trastuzumab-and-hyaluronidase-oysk","indication_name":"First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Trastuzumab and Hyaluronidase-oysk","company_name":"Adrienne G. Waks","drug_phase":"marketed","molecular_target":"HER2","drug_class":"Endoglycosidase [EPC]","quality_score":10,"revenue":null,"mechanism":"Trastuzumab inhibits HER2-overexpressing tumor cell proliferation and mediates ADCC, while hyaluronidase increases subcutaneous permeability for better drug absorption."},{"drug_id":"chembl-chembl1946170","indication_name":"Metastatic Colorectal Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"REGORAFENIB","company_name":"","drug_phase":"marketed","molecular_target":"RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2, TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAF V600E, SAPK2, PTK5, Abl, CSF1R","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Regorafenib inhibits multiple kinases involved in oncogenesis, angiogenesis, metastasis, and tumor immunity."},{"drug_id":"neo-bladder-construct","indication_name":"BRAF V600E Mutation-Positive Locally Advanced or Metastatic Anaplastic Thyroid Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"\"Neo-Bladder\" Construct","company_name":"Wake Forest University Health Sciences","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":29,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl3301589","indication_name":"Locally Advanced or Metastatic Urothelial Cancer (Combination Therapy)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ENFORTUMAB VEDOTIN","company_name":"","drug_phase":"marketed","molecular_target":"Nectin-4","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Enfortumab vedotin-ejfv binds to Nectin-4 on cancer cells, internalizes, releases MMAE, disrupting microtubules and causing cell death."},{"drug_id":"chembl-chembl359744","indication_name":"Metastatic Breast Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DOXORUBICIN HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"topoisomerase II","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA, inhibiting nucleotide replication, and forming DNA-cleavable complexes with topoisomerase II."},{"drug_id":"chembl-chembl3301589","indication_name":"Locally Advanced or Metastatic Urothelial Cancer (Single Agent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ENFORTUMAB VEDOTIN","company_name":"","drug_phase":"marketed","molecular_target":"Nectin-4","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Enfortumab vedotin-ejfv binds to Nectin-4 on cancer cells, internalizes, releases MMAE, disrupting microtubules and causing cell death."},{"drug_id":"chembl-chembl409","indication_name":"Stage D2 Metastatic Prostate Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"BICALUTAMIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Androgen Receptor Inhibitor [EPC]","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"datopotamab-deruxtecan","indication_name":"Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DATOPOTAMAB DERUXTECAN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl428647","indication_name":"Metastatic breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PACLITAXEL","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Microtubule Inhibitor [EPC]","quality_score":37,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl3545110","indication_name":"Initial endocrine-based therapy for advanced or metastatic breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"RIBOCICLIB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"faslodex","indication_name":"Metastatic Breast Cancer Progression Post-Antiestrogen Therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Faslodex","company_name":"Translational Oncology Research International","drug_phase":"marketed","molecular_target":"NAD-dependent protein deacylase sirtuin-5, mitochondrial, Bifunctional epoxide hydrolase 2, G-protein coupled estrogen receptor 1","drug_class":"","quality_score":16,"revenue":null,"mechanism":null}],"pipeline":[{"drug_id":"zn-c3","indication_name":"Metastatic Colorectal Cancer","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ZN-c3","generic_name":"zn-c3","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"ZN-c3 tablet by mouth, in combination with encorafenib","quality_score":0,"revenue":null,"mechanism":"ZN-c3 tablet by mouth, in combination with encorafenib"},{"drug_id":"olaparib-200-300-mg-bid-daily","indication_name":"Relapsed/refractory metastatic breast cancer (in combination with vorinostat)","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Olaparib 200-300 mg BID, daily","company_name":"Repare Therapeutics","drug_phase":"discontinued","molecular_target":"PARP1 and PARP2 (poly(ADP-ribose) polymerase enzymes)","drug_class":"PARP inhibitor (DNA damage response inhibitor)","quality_score":null,"revenue":null,"mechanism":"Olaparib inhibits PARP enzymes to block DNA single-strand break repair, inducing synthetic lethality in BRCA-mutant and HR-deficient cancers."},{"drug_id":"palbociclib-aromatase-inhibitor","indication_name":"Metastatic Breast Cancer","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib + aromatase inhibitor","generic_name":"palbociclib-aromatase-inhibitor","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"Palbociclib + aromatase inhibitor","quality_score":null,"revenue":null,"mechanism":"Palbociclib + aromatase inhibitor"},{"drug_id":"endocrine-therapy-1","indication_name":"HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Endocrine Therapy 1","generic_name":"endocrine-therapy-1","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"Endocrine Therapy 1","quality_score":null,"revenue":null,"mechanism":"Endocrine Therapy 1"},{"drug_id":"lutetium-177","indication_name":"Metastatic Castration Sensitive Prostate Cancer (mCSPC)","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lutetium-177","generic_name":"lutetium-177","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"mCRPC","quality_score":null,"revenue":null,"mechanism":"mCRPC"},{"drug_id":"endocrine-therapy-2","indication_name":"HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Endocrine Therapy 2","generic_name":"endocrine-therapy-2","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"Endocrine Therapy 2","quality_score":null,"revenue":null,"mechanism":"Endocrine Therapy 2"},{"drug_id":"sunitinib-and-capecitabine","indication_name":"Metastatic Colorectal Cancer","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"sunitinib and capecitabine","generic_name":"sunitinib-and-capecitabine","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"Sunitinib 37.5 mg po once daily Capecitabine 1000 mg po twice daily","quality_score":0,"revenue":null,"mechanism":"Sunitinib 37.5 mg po once daily Capecitabine 1000 mg po twice daily"},{"drug_id":"pf-06873600","indication_name":"HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06873600","generic_name":"pf-06873600","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"PF-06873600 tablet for oral dosing","quality_score":null,"revenue":null,"mechanism":"PF-06873600 tablet for oral dosing"},{"drug_id":"phytonadione","indication_name":"Metastatic colorectal cancer","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PHYTONADIONE","company_name":"","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase complex subunit 1 (VKORC1)","drug_class":"Vitamin K [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"lorviqua","indication_name":"Metastatic ALK+ Non Small Cell Lung Cancer","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lorviqua","generic_name":"lorviqua","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"Tyrosine-protein kinase FRK, ALK tyrosine kinase receptor, Activated CDC42 kinase 1","drug_class":"As provided in real world practice","quality_score":0,"revenue":null,"mechanism":"As provided in real world practice"},{"drug_id":"letrozole-2-5mg","indication_name":"Metastatic Breast Cancer","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Letrozole 2.5mg","generic_name":"letrozole-2-5mg","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"2.5 mg letrozole per day, administered orally (continuous treatment)","quality_score":null,"revenue":null,"mechanism":"2.5 mg letrozole per day, administered orally (continuous treatment)"}],"offLabel":[],"totalMarketed":190,"totalPipeline":11},"trials":{"data":[{"nct_id":"NCT05380336","title":"Medico-economic Evaluation Comparing the Impact of the New Fixed-dose Nivolumab Regimen With the Old mg/kg Regimen in the Management of Patients With Metastatic Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":40000,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT06106568","title":"An Observational Study to Learn More About the Impact of Gadoxetate Sodium-Enhanced Magnetic Resonance Imaging (EOB-MRI) When Used to Diagnose the Spread of Cancer From the Pancreas to the Liver in Japanese People Under Real-World Conditions","phase":"","overall_status":"COMPLETED","enrollment_count":39624,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06557967","title":"Study on Prevalence and Impact of Brain Metastases on Survival in Lung Cancer by Line of Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":22517,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT03676257","title":"Survival Endpoints in Women Treated for Metastatic Breast Cancer: Contribution of Real-life Databases","phase":"","overall_status":"COMPLETED","enrollment_count":20033,"lead_sponsor_name":"Institut Bergonié","has_results":true},{"nct_id":"NCT05217381","title":"Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 Status","phase":"","overall_status":"COMPLETED","enrollment_count":18533,"lead_sponsor_name":"MedSIR","has_results":false},{"nct_id":"NCT03871816","title":"A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":14532,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT05384002","title":"An AI Platform Integrating Imaging Data and Models, Supporting Precision Care Through Prostate Cancer's Continuum","phase":"","overall_status":"COMPLETED","enrollment_count":14000,"lead_sponsor_name":"Fondazione del Piemonte per l'Oncologia","has_results":false},{"nct_id":"NCT07476170","title":"Real-World Treatment Pattern and Clinical Outcome With Influential Factors of HR+/HER2-aBC 1L Patients in China","phase":"","overall_status":"RECRUITING","enrollment_count":14000,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06686602","title":"A Study Assessing Risk Factors for Oral Mucositis/Stomatitis and Ocular Surface Events in NSCLC and Breast Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":13759,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT05283044","title":"Implementing Precision Medicine in cOmmunity HospiTALs","phase":"NA","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Gustave Roussy, Cancer Campus, Grand Paris","has_results":false},{"nct_id":"NCT07342309","title":"Real-World Treatment Patterns and Outcomes in HER2-Altered Metastatic Breast Cancer Patients in the United States","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":7933,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT00068003","title":"Harvesting Cells for Experimental Cancer Treatments","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":7000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03577197","title":"Southeast Netherlands Advanced Metastatic Breast Cancer Registry","phase":"","overall_status":"RECRUITING","enrollment_count":7000,"lead_sponsor_name":"Academisch Ziekenhuis Maastricht","has_results":false},{"nct_id":"NCT06835218","title":"PROCARE - PROstate Cancer Real World Evidence Registry","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"UroTrials Company (GmbH)","has_results":false},{"nct_id":"NCT05652569","title":"CATCH: Implementation of Genomics-guided Precision Medicine in Metastatic Breast Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"German Cancer Research Center","has_results":false},{"nct_id":"NCT05141240","title":"A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors","phase":"","overall_status":"COMPLETED","enrollment_count":4650,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05153135","title":"Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors","phase":"","overall_status":"COMPLETED","enrollment_count":4320,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06805812","title":"Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study","phase":"","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT03461341","title":"European iNvestigation of SUrveillance After Resection for Esophageal Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":3000,"lead_sponsor_name":"St. James's Hospital, Ireland","has_results":false},{"nct_id":"NCT07386847","title":"A Real-world Study of the First Treatment and Outcomes of Patients With Advanced or Metastatic Bladder Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT05361655","title":"Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor","phase":"","overall_status":"COMPLETED","enrollment_count":2888,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05132101","title":"Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea","phase":"","overall_status":"COMPLETED","enrollment_count":2758,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT04989192","title":"Dose Efficiency of Modern CT Scanners in Oncologic Scans","phase":"NA","overall_status":"UNKNOWN","enrollment_count":2400,"lead_sponsor_name":"University Hospital Augsburg","has_results":false},{"nct_id":"NCT06029010","title":"An Observational Study to Learn More About the Long-Term Responses to Treatment With Regorafenib in Patients With Metastatic Colorectal Cancer in the United States","phase":"","overall_status":"COMPLETED","enrollment_count":2326,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05537922","title":"I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy","phase":"","overall_status":"RECRUITING","enrollment_count":2200,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT05933876","title":"The Impact of Radiotherapy on Oligometastatic Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Institut Investigacio Sanitaria Pere Virgili","has_results":false},{"nct_id":"NCT03758976","title":"Sweden Cancerome Analysis Network - Breast Recurrence (SCAN-B-rec)","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Lund University Hospital","has_results":false},{"nct_id":"NCT07484971","title":"Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Prostate Cancers in Algeria","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Société Algérienne de Formation et Recherche en Oncologie","has_results":false},{"nct_id":"NCT05043506","title":"European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal Therapies","phase":"","overall_status":"COMPLETED","enrollment_count":1939,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT04801186","title":"Retrospective Study to Describe the Real-world Treatment Patterns and Associated Clinical Outcomes in Patients With Metastatic Castration-resistant Prostates Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":1920,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05908799","title":"Emulation of the KEYNOTE-189 Trial Using Electronic Health Records","phase":"","overall_status":"COMPLETED","enrollment_count":1854,"lead_sponsor_name":"Aetion, Inc.","has_results":false},{"nct_id":"NCT06120491","title":"Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1800,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06204302","title":"An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States","phase":"","overall_status":"COMPLETED","enrollment_count":1800,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT02495974","title":"European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)","phase":"","overall_status":"COMPLETED","enrollment_count":1763,"lead_sponsor_name":"Astellas Pharma Europe Ltd.","has_results":false},{"nct_id":"NCT04757311","title":"Metastatic Colorectal Cancer. Real-World Data Analysis.","phase":"","overall_status":"COMPLETED","enrollment_count":1750,"lead_sponsor_name":"Istanbul Medeniyet University","has_results":false},{"nct_id":"NCT04314401","title":"National Cancer Institute \"Cancer Moonshot Biobank\"","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1600,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07344779","title":"A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1600,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT03786107","title":"HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib","phase":"","overall_status":"TERMINATED","enrollment_count":1583,"lead_sponsor_name":"Puma Biotechnology, Inc.","has_results":false},{"nct_id":"NCT02066961","title":"A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":1533,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT07200830","title":"Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":1524,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT02141438","title":"Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":1472,"lead_sponsor_name":"Bayer","has_results":true},{"nct_id":"NCT03396874","title":"Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":1435,"lead_sponsor_name":"University of Michigan","has_results":true},{"nct_id":"NCT04256993","title":"PRECISE, a Study to Gather More Information About Bone Fractures and Survival in Castration-resistant PRostate Cancer (CRPC) patiEnts Treated With Radium-223 in Routine Clinical practIce in SwedEn","phase":"","overall_status":"COMPLETED","enrollment_count":1434,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06975371","title":"Real-World Outcomes of Patients With Metastatic Breast Cancer After Treatment With First-Line ET+CDK4/6i","phase":"","overall_status":"COMPLETED","enrollment_count":1415,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT07222566","title":"Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1410,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT02003924","title":"Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1401,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT07406282","title":"A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics","phase":"","overall_status":"RECRUITING","enrollment_count":1400,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT02051218","title":"Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1380,"lead_sponsor_name":"Swiss Cancer Institute","has_results":false},{"nct_id":"NCT01039506","title":"An Observational Study of CPT-11 Based Regimens and UGT1A1 Genotypes in Metastatic Colorectal Cancer (mCRC)","phase":"","overall_status":"COMPLETED","enrollment_count":1376,"lead_sponsor_name":"Daiichi Sankyo Co., Ltd.","has_results":false},{"nct_id":"NCT06013475","title":"An Observational Cohort Study to Describe and Compare the Use of Darolutamide, Enzalutamide and Apalutamide and How Well These Work in Men With Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in Real World Settings","phase":"","overall_status":"COMPLETED","enrollment_count":1375,"lead_sponsor_name":"Bayer","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}